Revelation Biosciences (REVB) Other Non Operating Income (2021 - 2026)
Revelation Biosciences (REVB) posted quarterly Other Non Operating Income of $60495.0 for Q4 2025, up 136.2% year-over-year from $25612.0 in Q4 2024, and up 71.74% quarter-over-quarter from $35224.0 in Q3 2025.
Revelation Biosciences (REVB) Other Non Operating Income (2021 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Other Non Operating Income for 5 consecutive years, with $60495.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non Operating Income rose 136.2% year-over-year to $60495.0; the TTM figure through Dec 2025 stood at $155007.0 (up 102.17% YoY), while the FY2025 annual figure was $155007.0, up 102.17% from the prior year.
- Other Non Operating Income rose to $60495.0 in Q4 2025 per REVB's latest filing, from $35224.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $61621.0 in Q2 2023 and bottomed at -$5.9 million in Q2 2024.
- Historically, Other Non Operating Income has averaged -$339188.9 across 5 years, with a median of $21207.5 in 2024.
- Annual changes were most pronounced in 2022 — Other Non Operating Income jumped 5257.63% — and 2024, when it plunged 9628.96%.
- Revelation Biosciences' Other Non Operating Income stood at -$3439.0 in 2021, then jumped by 412.33% to $10741.0 in 2022, then surged by 410.05% to $54785.0 in 2023, then plunged by 53.25% to $25612.0 in 2024, then surged by 136.2% to $60495.0 in 2025.
- Business Quant data shows REVB's Other Non Operating Income at $60495.0 in Q4 2025, $35224.0 in Q3 2025, and $16803.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 338,857.00 |
| Dec 31, 2025 | 60,495.00 |
| Sep 30, 2025 | 35,224.00 |
| Jun 30, 2025 | 16,803.00 |
| Mar 31, 2025 | 42,485.00 |
| Dec 31, 2024 | 25,612.00 |
| Sep 30, 2024 | -450,920.00 |
| Jun 30, 2024 | -5.87 Mn |
| Mar 31, 2024 | -847,722.00 |
| Dec 31, 2023 | 54,785.00 |
| Sep 30, 2023 | 56,960.00 |
| Jun 30, 2023 | 61,621.00 |
| Mar 31, 2023 | 34,107.00 |
| Dec 31, 2022 | 10,741.00 |
| Sep 30, 2022 | 28,728.00 |
| Jun 30, 2022 | 25,734.00 |
| Mar 31, 2022 | -30,241.00 |
| Dec 31, 2021 | -3,439.00 |
| Sep 30, 2021 | -557.00 |
| Jun 30, 2021 | -27,714.00 |